Cost effectiveness analysis of respiratory syncytial virus infection prophylaxis in children with congenital heart disease
Cost effectiveness analysis of respiratory syncytial virus infection prophylaxis in children with congenital heart disease
| dc.contributor.author | Cintra, MACT | |
| dc.contributor.author | Santos, MS | |
| dc.contributor.author | Correia, MG | |
| dc.contributor.author | Tura, BR | |
| dc.date.accessioned | 2023-12-07T18:13:33Z | |
| dc.date.available | 2023-12-07T18:13:33Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | Objectives: Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory illness in children under two years of age. In Brazil, the VSR is the cause of 54.1% of all hospitalizations for pneumonia /bronchiolitis in infants under one year old, reaching up to 70% during the epidemic periods. Congenital heart disease (CHD) is an important risk factor for morbidity and mortality of RSV infection. This study performed a cost effectiveness analysis of Palivizumab (PVZ) to prevent RSV infection in infants undergoing cardiac surgery for correction of CHD. Methods: Three Systematic Reviews (SR) of literature were performed, in Medline, Cochrane and LILACS, for efficacy, safety of PVZ and the prevalence of RSV in infants in Brazil. The economic evaluation developed a decision analytic model to estimate the cost effectiveness ratio of using PVZ for prophylaxis of RSV infection in children under going cardiac surgery, from the perspective of Public Health System, with the time horizon of the postoperatively period. Results: Efficacy search (478 titles) showed that PVZ reduces hospitalization for children with CHD by 45%. Safety search (67 titles) showed that the PVZ is safe for this population and the prevalence of RSV in Brazil search (120 titles) showed that in children hospitalized with lower respiratory tract infection there is a prevalence of 24.35% of RSV infection. The analytical model showed an incremental cost-effectiveness ratio of USD863.3 per day of hospitalization avoided and incremental cost-effectiveness ratio of USD132,398.9 per complication avoided. Conclusions: The prevalence of RSV in Brazil is 24.35%. PVZ was effective and safe to prevent severe RSV infection in children under two years of age with CHD, but at a high cost to avoid an outcome. Its use has shown a significant decrease in hospitalization of children receiving medication. Studies published worldwide are controversial, requiring discussion for the implementation of the therapy in Brazil. | |
| dc.identifier.citation | Cintra MACT, Santos MS, Correia MG, Tura BR. Cost effectiveness analysis of respiratory syncytial virus infection prophylaxis in children with congenital heart disease. Value Health. 2014;17:A176. | |
| dc.identifier.uri | https://dspace.inc.saude.gov.br/handle/123456789/379 | |
| dc.language.iso | en | |
| dc.publisher | Value in Health | |
| dc.title | Cost effectiveness analysis of respiratory syncytial virus infection prophylaxis in children with congenital heart disease | |
| dc.type | Article |